© 2020 MJH Life Sciences and Contemporary OB/GYN. All rights reserved.
Breast Health
Insulin resistance contributes to racial disparities in breast cancer prognosis in US women
August 04, 2020
The lack of data on the possible connection between race and breast cancer prognosis is what led a group of Mount Sinai researchers to conduct this new multicenter, cross-sectional study.
Menopausal hormone therapy and mortality in breast cancer survivors
July 30, 2020
A study from the Long Island Breast Cancer Study Project (LIBCSP) investigated the association between menopausal hormone therapy (MHT) and mortality outcomes among breast cancer survivors.
Supportive care underutilized by breast cancer survivors
July 29, 2020
New research shows that, when seeking treatment for cancer-related fatigue, breast cancer survivors underutilize recommendations.
Pregnancy after breast cancer in patients with germline BRCA mutations
July 24, 2020
The study in the Journal of Clinical Oncology is a follow-up to a study conducted by the same authors to evaluate if pregnancy is safe in breast cancer patients who have hormone-sensitive breast cancer.
Improving risk outcomes: Invasive breast cancer after DCIS
July 08, 2020
Women with ductal carcinoma in situ (DCIS) may experience higher risk of developing invasive breast cancer (IBC) and of death from breast cancer than the general population, according to new research.
Aromatase inhibitors for climacteric symptoms in women with breast cancer
July 08, 2020
New research shows that, in postmenopausal women undergoing hormone therapy for breast cancer, aromatase inhibitors (AIs) lead to a reduction in climacteric symptoms and significantly improved quality of life.
Link between hormone replacement therapy and mammographic density
July 06, 2020
The review concluded that the highest increase in MD is among current users of HRT, particularly those taking continuous estrogen plus progestin (CEP).
Breast density laws and patient knowledge
June 23, 2020
Currently, 38 states and the District of Columbia have enacted dense breast notification (DBN) laws mandating that mammogram results include language informing women of risks related to dense breasts.
PARP inhibitors: Choosing what to use in epithelial ovarian cancer
June 23, 2020
Across different drugs and clinical settings, use of PARPi has resulted in a prolonged period without cancer recurrence.
Survival benefit in advanced or metastatic breast cancer with visceral metastases
June 12, 2020
Findings from a new study show significant overall survival benefit of Novartis’ ribociclib in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer with visceral metastases.